diseas
fmd
highli
contagi
acut
diseas
affect
domest
wild
anim
clinic
symptom
includ
fever
lame
vesicular
lesion
feet
tongu
snout
diseas
control
includ
sacrif
infect
suscept
anim
inhibit
anim
movement
disinfect
contamin
premis
vaccin
suscept
howev
vaccin
recommend
due
sever
reason
includ
technic
limit
distinguish
vaccin
infect
anim
differ
antigen
variabl
strain
viru
trade
result
oie
recogn
effect
control
measur
includ
vaccin
combin
use
antivir
agent
andor
immunomodulatori
molecul
could
rapidli
control
diseas
adapt
immun
respons
interferon
ifn
group
cytokin
divid
three
type
includ
type
type
ii
type
iii
constitut
first
step
immun
respons
type
ifn
includ
largest
group
interferon
famili
action
viral
gene
initi
found
human
thirti
year
ago
sinc
identifi
anim
except
canin
similar
ifn
produc
cell
respons
viral
infect
ident
antivir
antiprolif
immunomodulatori
activ
bind
receptor
activ
similar
pathway
felin
first
licens
interferon
compound
use
cat
treatment
felin
immunodefici
viru
felin
leukemia
viru
infect
virbac
europ
japan
australia
new
zealand
unfortun
util
viral
infect
fact
also
exert
protect
effect
sever
virus
includ
bovin
enteroviru
bovin
viral
diarrhea
viru
infecti
bovin
rhinotrach
viru
influenza
viru
european
bat
lyssaviru
vesicular
stomat
viru
pseudorabi
viru
canin
felin
parvoviru
herpesviru
caliciviru
coronaviru
howev
antivir
effect
never
assess
fmdv
interestingli
differ
subtyp
distinct
antivir
activ
vitro
vivo
exampl
among
four
pseudogen
eight
function
gene
porcin
famili
porcin
ifn
omega
highest
antivir
activ
approxim
time
lowest
antivir
addit
lower
vitro
cytotox
compar
interferon
make
therapeut
candid
treat
viral
studi
express
escherichia
coli
antivir
effect
fmdv
assess
vitro
cell
maintain
laboratori
e
coli
cell
purchas
solarbio
beij
china
two
differ
serotyp
fmdv
strain
use
investig
antivir
activ
measur
reed
muench
dna
sequenc
matur
gene
access
synthes
shanghai
sangon
biotechnolog
co
ltd
shanghai
china
digest
ecori
hind
iii
restrict
site
vector
target
gene
ligat
correspond
site
vector
invitrogen
ca
follow
ligat
result
vector
transform
chemic
compet
e
coli
cell
singl
coloni
identifi
coloni
polymeras
chain
reaction
pcr
use
forward
primer
revers
primer
dna
sequenc
shanghai
sangon
biotechnolog
co
ltd
e
coli
cell
use
host
strain
overexpress
protein
firstli
posit
recombin
plasmid
transform
induc
e
coli
express
stain
final
concentr
mm
iptg
sigma
ad
induc
protein
express
e
coli
cell
optic
densiti
reach
time
bacteria
cultur
hour
centrifug
rpm
minut
harvest
cell
final
volum
ml
buffer
vv
lysozym
mm
ethylenediaminetetraacet
acid
edta
vv
triton
mm
ph
sonic
w
second
second
inclus
bodi
ib
gain
centrifug
minut
wash
three
time
buffer
ib
final
volum
ml
buffer
b
urea
mm
mm
ph
incub
overnight
solut
centrifug
rpm
minut
supernat
collect
subsequ
supernat
load
onto
ml
nickel
sepharos
fast
flow
column
remov
bound
materi
column
wash
ml
buffer
b
next
column
wash
linear
gradient
imidazol
mm
mm
imidazol
buffer
b
use
ml
step
final
target
protein
elut
mm
imidazol
buffer
b
fraction
contain
protein
pool
identifi
sodium
dodecyl
gel
electrophoresi
purifi
protein
renatur
reduc
concentr
urea
buffer
c
mm
tri
mm
edta
glycin
glycerinum
ph
final
protein
concentr
measur
bradford
protein
assay
kit
amresco
western
blot
analysi
use
confirm
endotoxin
analyz
genscript
chromogen
lal
endotoxin
assay
kit
genscript
accord
instruct
manufactur
antivir
activ
purifi
protein
test
use
cell
fmdv
previous
briefli
cell
grown
dulbecco
modifi
eagl
medium
dmem
gibco
supplement
fetal
bovin
serum
fb
penicillin
uml
streptomycin
cell
seed
per
well
plate
incub
hour
incub
serial
dilut
ad
cell
incub
addit
hour
time
supernat
remov
wash
three
time
dmem
cell
infect
fmdv
hour
cultur
supernat
replac
dmem
contain
fb
penicillin
uml
streptomycin
hour
incub
control
uninfect
cell
cell
control
infect
fmdv
absenc
cell
viru
control
maintain
hour
viabil
cell
calcul
use
mt
assay
kit
abcam
uk
accord
manufactur
instruct
base
od
read
nm
percent
protect
cytopath
effect
cpe
measur
previous
describ
kawamoto
et
total
rna
cell
lysat
extract
hour
use
trizol
reagent
invitrogen
rel
rna
express
level
fmdv
assess
quantit
pcr
primer
set
tabl
describ
antivir
activ
fmdv
test
use
similar
method
describ
differ
cell
challeng
fmdv
cell
infect
fmdv
method
describ
monolay
cell
seed
plate
infect
fmdv
wash
three
time
dmem
ngml
ad
cell
hour
infect
respect
control
cell
control
viru
control
well
maintain
hour
cell
viabil
viral
mrna
express
level
measur
describ
monolay
cell
seed
plate
treat
ngml
untreat
cell
maintain
control
group
hour
later
cell
scrape
well
subsequ
total
rna
extract
use
trizol
reagent
invitrogen
treat
dnase
takara
dalian
china
accord
manufactur
protocol
concentr
extract
rna
measur
use
nanodrop
thermo
fisher
scientif
quantit
revers
perform
describ
list
primer
sequenc
shown
tabl
reaction
compris
sybr
green
cdna
pmol
primer
water
total
volum
program
start
second
denatur
follow
cycl
second
denatur
second
anneal
second
elong
specif
primer
fluoresc
measur
experi
contain
neg
control
reaction
perform
triplic
dna
contamin
rna
sampl
check
pcr
use
control
reaction
mix
revers
transcriptas
enzym
porcin
use
endogen
control
normal
differ
amount
total
rna
cell
rel
quantiti
mrna
accumul
evalu
use
threshold
cycl
data
present
mean
standard
deviat
sd
least
triplic
experi
statist
signific
analyz
anova
use
spss
softwar
packag
follow
tukey
multipl
comparison
test
graphic
illustr
produc
graphpad
prism
softwar
version
version
valu
p
consid
statist
signific
accord
sequenc
avail
ncbi
nucleotid
sequenc
synthes
use
express
vector
contain
sequenc
one
hexahistidin
tag
fuse
figur
recombin
identifi
pcr
dna
sequenc
confirm
gene
accord
design
bp
length
data
shown
select
recombin
plasmid
transform
e
coli
protein
express
induc
iptg
protein
consider
express
e
coli
strain
yield
protein
approxim
mgl
bacteri
cultur
shown
figur
mass
inclus
protein
detect
use
agaros
imac
column
buffer
contain
imidazol
puriti
recombin
protein
obtain
yield
mgl
bacteri
cultur
figur
subsequ
protein
identifi
western
blot
analysi
figur
endotoxin
undetect
purifi
recombin
protein
detect
limit
eumg
investig
minimum
protect
antivir
concentr
purifi
protein
cell
serial
dilut
ngml
ngml
ad
five
replic
cell
lowest
dilut
offer
protect
cell
cpe
ngml
display
protect
howev
lower
dilut
use
exert
effici
protect
cpe
caus
type
fmdv
figur
concentr
ngml
decreas
viral
mrna
level
titer
respect
compar
vc
group
figur
consider
differ
cpe
effect
observ
ngml
ngml
group
well
concentr
group
vc
group
p
addit
could
also
exert
antivir
activ
type
fmdv
figur
concentr
ngml
exhibit
near
prevent
cpe
caus
type
fmdv
figur
evalu
whether
could
protect
cell
cpe
follow
viral
infect
antivir
effect
investig
ngml
ad
cell
hour
post
infect
respect
result
show
show
protect
cpe
hour
figur
display
decreas
fmdv
mrna
level
hour
figur
comparison
group
howev
compar
vc
group
display
consider
cpe
viral
mrna
level
remark
protect
found
cpe
viral
amount
downregul
hour
hour
post
infect
figur
better
illustr
mechan
antivir
activ
elicit
cell
mrna
level
isg
includ
pkr
cell
control
group
analyz
shown
figur
compar
control
group
mrna
express
antivir
gene
pkr
mrna
cell
treat
higher
respect
figur
ifn
report
year
ago
isaac
lindenmann
antivir
protein
gener
respons
viral
ifn
constitut
first
step
immun
respons
pathogen
infect
result
induct
ifn
power
tool
host
fight
viral
case
fmdv
strategi
demonstr
effici
biotherapeut
option
besid
demonstr
fusion
protein
could
protect
fmdv
infect
induc
type
ifn
howev
antivir
effect
fmdv
still
unknown
herein
studi
first
time
activ
demonstr
vitro
concentr
determin
studi
found
lowest
concentr
ngml
provid
protect
cell
cpe
caus
interestingli
concentr
could
also
exert
signific
protect
cell
infect
figur
fact
unlik
vaccin
ifn
exert
antivir
activ
lot
virus
matter
serotyp
strain
result
similar
studi
usharani
et
studi
found
also
exert
antivir
effect
eight
strain
fmdv
studi
ngml
also
provid
cell
consider
protect
cpe
display
reduct
viral
mrna
level
hour
compar
vc
group
figur
viral
mrna
level
increas
hour
rais
consider
hour
consider
cpe
observ
period
result
suggest
might
serv
use
adjunct
treatment
onset
fmd
outbreak
well
within
hour
exposur
fmdv
gener
type
ifn
trigger
product
antivir
effector
mediat
jakstat
pathway
effector
includ
isg
oa
result
show
enhanc
mrna
level
pkr
howev
signal
verifi
phosphoryl
effector
use
studi
studi
still
need
help
elucid
porcin
ifn
antivir
innat
immun
address
question
exert
differ
biolog
activ
although
use
type
signal
pathway
sever
studi
reveal
combin
interferon
therapi
enhanc
protect
comparison
singl
interferon
instanc
result
studi
mora
et
reveal
combin
synergist
effect
suppress
fmdv
replic
vitro
vivo
futur
studi
import
assess
whether
combin
type
ii
ifn
lead
increas
efficaci
fmdv
besid
enhanc
inhibit
effect
fmdv
also
observ
combin
ribavirin
vivo
vitro
therefor
whether
combin
ribavirin
enhanc
antivir
activ
also
demonstr
studi
although
antivir
effect
demonstr
fmdv
vitro
studi
confirm
vivo
activ
use
anim
suckl
mice
note
mice
howev
target
speci
includ
bovin
porcin
need
futur
confirm
antivir
effect
evalu
true
potenti
adjunct
control
measur
fmd
outbreak
recent
year
increas
interest
studi
consensu
interferon
type
ifn
contain
frequent
occur
amino
acid
present
among
subtyp
shown
higher
antivir
activ
natur
killer
cell
activ
activ
compar
singl
ifn
likewis
porcin
multigen
famili
contain
seven
subtyp
differ
antivir
activ
differ
express
therefor
consensu
could
also
design
efficaci
fmdv
investig
futur
studi
conclus
exhibit
vitro
antivir
activ
fmdv
provid
new
insight
develop
novel
antivir
molecular
use
combin
vaccin
treatment
would
thu
protect
anim
earli
stage
fmd
viral
infect
onset
immun
respons
author
declar
conflict
interest
hc
yz
conceiv
design
experi
fs
mg
perform
experi
fz
js
yl
yx
help
analyz
data
fs
mg
wrote
paper
author
read
approv
final
manuscript
